Altimmune (ALT) is now covered by Truist Financial Corporation. They set a "buy" rating and a $12.00 price target on the stock.
Altimmune (ALT) had its price target raised by HC Wainwright from $12.00 to $25.00. They now have a "buy" rating on the stock.
Altimmune Touts Pemvidutide Progress, Targets MASH Phase 3 Start and Q3 AUD Readout at Barclays Chat [Yahoo! Finance]
Altimmune Details Pemvidutide MASH Path: Breakthrough Therapy, FDA Feedback, Phase 3 Next Up [Yahoo! Finance]
Altimmune (ALT) had its price target lowered by B. Riley Financial, Inc. from $18.00 to $13.00. They now have a "buy" rating on the stock.